Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition

BOSTON--(BUSINESS WIRE)--Dec 11, 2023--

Related Keywords

Boston ,Massachusetts ,United States ,Saudi Arabia ,Australia ,Bahrain ,London ,City Of ,United Kingdom ,America ,American ,Saudi ,Great Britain ,Exagamglogene Autotemcel ,Heather Nichols ,Manisha Pai ,Carmen Bozic ,Exchange Commission ,Facebook ,Global Medicines Development ,Vertex Pharmaceuticals Incorporated Nasdaq ,American Society Of Hematology ,Vertex Pharmaceuticals Incorporated ,Drug Agency ,Occlusive Crisis On Health ,Regulatory Agency ,National Health Regulatory Authority ,Linkedin ,Companies To Work ,Instagram ,European Medicines Agency ,Youtube ,Drug Administration ,Improvements In Health ,Pharmaceuticals Incorporated ,American Society ,Annual Meeting ,Executive Vice President ,Medical Affairs ,Chief Medical Officer ,Prescription Drug User Fee Act ,Severe Sickle Cell ,Health Related Quality ,Life After Exagamglogene Autotemcel ,Transfusion Dependent Beta ,Patients With Severe Sickle Cell ,Status Among Patients ,Cohort Study ,Recent Vaso Occlusive Crisis ,Sickle Cell ,Sickle Cell Disease Prevalence ,Model Using ,Foreign Born State Specific Population ,Sickle Cell Disease ,Transfusion Dependent Beta Thalassemia ,Saudi Food ,Prescribing Information ,Patient Information ,North America ,Top Employers ,Private Securities Litigation Reform Act ,Vertex Pharmaceuticals ,Business Wire ,Region ,